You are here: Home » Companies » News
Business Standard

Bharat Biotech to test swine flu vaccine in 2 months

B Krishna Mohan  |  Hyderabad 

Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech, which is getting ready with an indigenous H1N1 swine flu candidate vaccine, would go for clinical trials in two months, according to its chairman and managing director Krishna M Ella.

Bharat Biotech apart, two other Indian - Serum Institute of India and Panacea - are also making the vaccine.

Speaking to Business Standard, Ella said swine flu has not reached a stage where it could not be controlled. He, however, did not give a timeframe in which the trials would be completed. “It all depends on the government,”’ he said, adding that the government has eased the clinical trial norms. He did not elaborate on how many doses of the vaccine would be needed to give protection against the virus.

According to him, diseases would continue to come. “First it was avian flu, now it is A H1N1. Tomorrow, it could be H2N2,” he said, adding that the changing environment and deforestation contribute to the increasing disease burden in the country. The company invested about Rs 7 crore for the vaccine and has a capacity to produce 10 million doses. But it would raise the capacity depending on the need, he said.

Early this month, the Union health ministry said it would place orders for the vaccines once the declare the number of dosages required.

Among others, Bharat Biotech supplies more than 300 million doses of polio vaccines in the country and exports the Hepatitis B vaccine to many countries.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 28 2009. 00:42 IST
RECOMMENDED FOR YOU
.